KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

For the Liu Lab, necessity is truly the mother of invention. The researchers were examining how the 3D organization of the ...

With further testing, discovery may offer new target for early detection and treatmentResearchers at Case Western Reserve ...

Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, ...

This listicle explores four major RNA therapeutic modalities, highlighting their breakthroughs, challenges and future ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development ...

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

As we continue to advance our Axiomer ADAR-mediated RNA editing platform and pipeline, ProQR is entering a pivotal phase of growth and ...